11 results about "Immunoactivators" patented technology

Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patients antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

The application discloses an application of ergothioneine in antiviral in the field of biotechnology. The ergothioneine plays an immune activation role at least by activating TLR4 and downstream NF-kappa B signal pathways. The ergothioneine is used for preparing an immunomodulator or an antiviral drug, can effectively activate immune cells and enhance antiviral capacity, to a certain extent, overcomes defects of traditional technologies, reduces problems of large side effects of current TLR4 agonists, and provides a new idea for developing a novel immunomodulator and an antiviral treatment strategy.

Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one-step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti-cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patient's antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

The present invention provides a hyperthermia-induced gut microbiome- mediated modulation of the host immune system for the treatment of gastric / gastric MALT / Duodenum cancer; the said system uses a wild type / non-pathogenic / attenuated strain coated with iron oxide nanoparticles to specifically target the cancerous tissue by applying an external field around the gastric tissue the said iron oxide generates heat on bacteria surface and causes lysis of bacteria in the tumor microenvironment; the lysis of bacteria triggers various potent immune activator and cytokines to activate antigen-presenting cells including lymphocytes and macrophages; the said antigen presenting cell further, eliminates cancer cell from the gut microenvironment and eventually clean tumor microenvironment. Additionally, the activated lymphocytes will be antigenic memory against bacterial particles and cancer tissues. Furthermore, the said treatment system does not involve the use of any chemotherapeutic drug or radiation treatment and, thus, precludes undesirable side effects of chemotherapy as well as minimizes toxicity.

The invention relates to the technical field of plant protection, in particular to a cryphonectria parasitica prevention and control method using validamycin as an immune activator to be mixed with biocontrol bacterium fermentation filtrate. According to the technical scheme, the method comprises the following steps: preparing a culture medium by using different concentrations of validamycin solutions and bacillus velezensis B268 fermentation filtrate diluted by different multiples, transferring the culture medium to a bacterial cake for culture, performing indoor toxicity determination, spraying three treatment groups according to a result obtained in the step 2 as a spraying concentration, performing living body inoculation after spraying a medicament for 1 day, and performing secondary inoculation after the medicament is sprayed for 1 day. After inoculation, collecting each group of leaves for defensive enzyme activity determination and MDA content determination, and collecting part of samples for transcriptome sequencing. The validamycin and the bacillus velezensis B268 fermentation filtrate are mixed to play a synergistic effect, so that the disease prevention effect is improved.

The invention belongs to the technical field of medicines, and particularly relates to ROS (reactive oxygen species) double-response nanoparticles for co-delivery of metabolic inhibitors and immune activators as well as a preparation method and application of the ROS double-response nanoparticles. The nanoparticles comprise a phenylboronic acid ester modified polymer which responds to ROS cracking, a ferrocene modified polymer which responds to ROS catalytic Fenton reaction, S-Gboxin which inhibits mitochondrial ATP synthesis, and a TGF-beta inhibitor Galunissertib which regulates immunity. The nanoparticles are targeted to Glut1 through DHA to mediate tumor targeting, and after entering tumor tissues and incorporating cells, the nanoparticles respond to ROS phenylboronic acid ester splitting decomposition, and drug release is accelerated; and under the catalysis of ferrocene, the common ROS in the tumor cells is converted into the superoxide compound with higher oxidation capacity. The released S-Gboxin is combined with the inner membrane of mitochondria, so that the membrane potential is reduced, and the tumor energy supply is inhibited. Similarly, the Galunissertib down regulates the tumor microenvironment TGF-beta, inhibits the expression of proteins pSMAD2 / 3 and TSP-1, and remodels the immunosuppressive microenvironment.

The invention relates to genetic engineering and medicine, in particular to application of rhodinine in preparation of T cell activation drugs. The invention provides an application of rhodinine in preparation of a medicine of a T cell activator. The method comprises the following steps: detecting the GFP fluorescence intensity of the NFAT-GFP report Jurkat T by using an InucyteSX5 high-throughput living cell analyzer, screening an immune activator from a natural compound library, detecting the NFAT-GFP report Jurkat T by using the Inucyte high-throughput living cell analyzer, and carrying out secondary screening, so as to obtain the rose tree alkali capable of effectively activating T cells. According to the present invention, the T cell activation performance of the rhodinine is verified through the research on the activation of the NFAT transcription factor by the rhodinine and the research on the influence of the rhodinine on the expression of the CD25 on the surface of the NFAT-GFP report Jurkat T cell;

The invention belongs to the technical field of preparation of immune activators, and particularly relates to a preparation method of an autoimmune activator. The invention provides a preparation method of an autoimmune activator, which comprises the following steps: separating an albuginea layer from peripheral blood, then respectively preparing an autoimmune exosome and an autovariant cell immune antigen through the steps of resuspension counting, water bath heating, programmed cooling, unfreezing centrifugation and the like, and mixing, freezing and drying to obtain the autoimmune activator. The technical scheme is simple and convenient, the obtained autoimmune activator is high in activity, and after subcutaneous injection, the autoimmune activator can effectively activate subcutaneous Langerhans cells, dendritic cells and the like, enhance the recognition ability of DC cells on antigens, induce Langerhans cells / DC cells to activate Th cells, enhance the effect of effector T cells and remove in-vivo variant cells, so that the autoimmune activator has a good immunogenicity. Therefore, autoimmune diseases or other health problems with immune imbalance states are improved, and the composition is safe and free of side effects.

Disclosed herein are compositions comprising immune-activating agents that bind the tumor cell surface in the absence of a tumor-targeting protein component. Described herein are methods and compositions for targeting a TLR or STING agonist to tumor cells and / or cells in the tumor microenvironment. It is hypothesized that the metabolic stress of tumor growth also produces an excess of unpaired cysteines on cell surface proteins relative to the rest of the body. Therefore, this chemistry can be used with compounds that would preferentially target unpaired cysteines on cell surface proteins.

The invention discloses an exosome-coated spherical ICG photoimmune activator CND-ICG at Exo as well as a preparation method and application thereof, and belongs to the technical field of nano biological medicines. The photoimmune activator is prepared by forming a CND-ICG compound from a carbon dot material CND and indocyanine green ICG through an esterification reaction and then wrapping tumor cell exosomes TDEs through an ultrasonic method. Through covalent coupling of CND and ICG, the defects that free ICG is poor in light stability, low in water solubility and rapid in-vivo elimination are overcome; by combining the tumor targeting and immune activation capability of TDEs, the photoimmune activator is efficiently enriched at the tumor site of triple negative breast cancer TNBC, the synergistic effect of photothermal tumor killing and immune activation can be achieved under laser irradiation, and meanwhile, the near-infrared imaging function is achieved. The activator is high in tumor cell killing rate and good in biological safety, and a new technical scheme is provided for precise diagnosis and treatment integration of TNBC.

Dislcosed is an immunoactivator that is capable of enhancing induction of both humoral immunity and cellular immunity and contains an active ingredient derived from cell walls (derived from a natural product); a vaccine adjuvant; and a method for inducing immunity including administering the immunoactivator. Theimmunoactivator contains, as an active ingredient, particles having a maximum diameter within a range of 1 to 800 nm, wherein the particles comprise cell-wall-derived polysaccharides.